Precision Therapeutics for Cancers and Immune Disorders

Latest News

Vividion Therapeutics Appoints Christine Siu to Board of Directors

+Read More

Vividion Therapeutics is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for cancers and immune disorders. We believe our novel, industrial scale chemoproteomic platform provides us with an opportunity to remove boundaries of druggability and develop therapies for patients with critical unmet medical needs across multiple therapeutic areas.

Our Approach

PROPRIETARY COVALENT
CHEMISTRY-BASED LIBRARY

Through iterative cycles of design and proteome-wide testing, we have built and continue to refine a library of cysteine-reactive small molecules specifically designed to enter and form covalent bonds with accessible cysteine residues located in shallow binding pockets in proteins in their native conformations. Our growing covalent chemistry-based library consists of over 15,000 highly diverse covalent reactive group (CRG)-bearing small molecules that thoroughly exploit three-dimensional space. Our ability to monitor covalent interactions across the proteome enables the continuous “proteome education” of our library.

NOVEL CHEMOPROTEOMICS
SCREENING TECHNOLOGY

Our screening technology is designed to sensitively and precisely detect small molecule interactions with proteins in their native cellular context at scale. This technology uses high resolution mass spectrometry and chemical “probes” to detect the interactions between small molecules and any protein regardless of functional class. Our approach allows us to efficiently mine the proteome to find cryptic functional pockets that were previously undiscovered or thought to be undruggable.

INTEGRATED
DATA PORTAL

Our data portal interprets the volume of data generated by our chemoproteomic platform with a standard output of approximately 100,000 new data points per day. The portal is a cloud-based web interface that is designed to overlay our internally generated data with the latest public resources for human genetics and structural biology. Integrating these data streams allows us to generate unique insights into accessible pockets and focus our discovery efforts on previously undruggable targets. Our data portal currently holds over 75 million compound-target site interaction measurements from which algorithms can be trained and refined to drive proprietary insights into covalent drug discovery.

Our Programs

Our chemical library and chemoproteomic screening technology are seamlessly integrated and evolve together.

The discovery of druggable pockets on disease-related proteins increases as our covalent chemistry-based library of small molecules expands. Altogether, our platform has enabled us to identify hundreds of previously unknown or cryptic functional pockets on well-validated protein targets implicated in a wide range of oncologic and immunologic diseases, while simultaneously identifying compounds from our proprietary covalent chemistry library that interact in a highly selective manner with those pockets. Our approach allows us to diversify our drug development efforts across multiple modalities, including allosteric activators and inhibitors, protein stabilizers, protein-protein interaction, or PPI, inhibitors and protein degraders.

Leveraging our team’s chemistry, biology and drug development expertise, we are advancing a deep and diversified pipeline of highly selective small molecule therapeutics targeting high value disease-causing proteins in oncology and immunology. Our lead programs target a key transcription factor, NRF2, along the KEAP1-NRF2 axis, for which we own world-wide rights. We are advancing our NRF2 programs for the potential treatment of NRF2 mutant cancers, as well as inflammatory diseases, including irritable bowel disease and chronic kidney disease.

In addition to our NRF2 program, we are evaluating a second program targeting an undisclosed transcription factor that we are advancing in collaboration with Bristol-Myers Squibb for inflammatory diseases and cancer.

We are also developing programs against other high value targets known to drive cancer and immune disease. Although we are currently focused on oncology and immunologic diseases, our internal capabilities provide a clear opportunity to expand into other disease areas of high unmet need in the future.

Publications

Abstract 6411: Discovery of covalent ligands to novel E3 ligases enables bispecific degraders with highly differentiated protein degradation across a broad range of targets,
AACR 2020
Read Publication
Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer,
Cell
Read Publication
DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras,
JACS
Read Publication
Discovery of covalent ligands to novel E3 ligases enables bispecific degraders with highly differentiated protein degradation across a broad range of targets,
AACR 2020
Read Publication
Fragment-based covalent ligand discovery,
RSC
Read Publication
The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer,
Annual Review of Cancer Biology 2020
Read Publication
Proteome-wide covalent ligand discovery in native biological systems,
Letter
Read Publication

Team

Our approach is made possible by a high-performing team of chemistry, biology, drug development and business experts who have a strong connection to our mission of bringing forward medicines that can make a potentially profound and broad impact on patients across the globe.

Benjamin F. Cravatt

X

Benjamin F. Cravatt is a Professor and Co-Chair of the Department of Molecular Medicine at The Scripps Research Institute. His research group is interested in understanding the roles that enzymes play in physiological and pathological processes, especially as pertains to the nervous system and cancer.  Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History.  He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996. Professor Cravatt joined the faculty at TSRI in 1997. Dr. Cravatt is a co-founder and scientific advisor of Activx Biosciences, Abide Therapeutics, and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the Protein Society Irving Sigal Young Investigator Award, the Tetrahedron Young Investigator Award in Bioorganic and Medicinal Chemistry, the ASBMB Merck Award, and memberships in the National Academy of Sciences and American Academy of Arts and Sciences.

Phil S. Baran

X

Phil Baran received his B.S. in chemistry from NYU in 1997, his Ph.D. at The Scripps Research Institute in 2001, and from 2001-2003 he was an NIH-postdoctoral fellow at Harvard. Dr. Baran began his independent career at Scripps in the summer of 2003. He currently holds the Darlene Shiley Chair in Chemistry. He has published over 180 scientific articles and has been the recipient of several ACS awards such as the Corey (2015), Pure Chemistry (2010), Fresenius (2006), and Nobel Laureate Signature (2003), and several international distinctions such as the Hirata Gold Medal and Mukaiyama Prize (Japan), the RSC award in Synthesis (UK), and the Sackler Prize (Israel). In 2013 he was named a MacArthur Foundation Fellow, in 2015 he was elected to the American Academy of Arts and Sciences, and in 2016 he was awarded the Blavatnik National Award.

Dr. Baran has delivered hundreds of lectures around the world and consults for numerous companies such as Bristol-Myers Squibb (since late 2005), Boehringer-Ingelheim, AstraZeneca, DuPont and TEVA, and is a scientific advisory board member for Eisai, Abide, and AsymChem. In 2016 he was appointed as an Associate Editor for the Journal of the American Chemical Society. He co-founded Sirenas Marine Discovery (2012) and Vividion Therapeutics (2016) and in 2013 he co-authored The Portable Chemist’s Consultant, an interactive book published on the iBooks store along with his graduate class in Heterocyclic Chemistry (viewable for free by anyone on iTunes University). Outside of the lab, Phil enjoys spending time with his wife Ana and three young children (Lucia, Leah, and Manuel).

Jin-Quan Yu

X

Jin-Quan Yu received his B.S. in Chemistry at East China Normal University, where he worked with Professor Li-Xin Dai and Professor Bi-Qi Wu as a visiting student at Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 1987. Following a one-year course study in Shanghai Institute of Organic Chemistry, Dr. Yu went to Guangzhou Institute of Chemistry, Chinese Academy of Sciences to study terpene chemistry and heterogeneous catalysis under the supervision of Professor Shu-De Xiao and obtained his Master’s degree in 1990. He stayed on as a research associate for four years and went to Cambridge University for his doctoral studies under the supervision of Dr J. B. Spencer, where he studied biosynthesis and the mechanistic details of the hydrometallation step in asymmetric hydrogenation. Dr. Yu was elected as a Junior Research Fellow of St John’s College, Cambridge University in 1998. From 2001-2002, Jin-Quan worked on Pd-catalyzed allylic oxidation as a postdoctoral fellow at the Harvard University in the laboratories of Professor E. J. Corey. He returned to Cambridge University in 2002 and was appointed as a University Royal Society Research Fellow in 2003 to start his independent research towards developing asymmetric C–H insertion reactions. In 2004, he moved to Brandeis University as an Assistant Professor of Chemistry. He joined The Scripps Research Institute as an Associate Professor in 2007 and became a full Professor in August 2010. He was appointed as the Frank and Bertha Hupp Professor of Chemistry at The Scripps Research Institute in 2012. He received Mukaiyama Award in 2012, the Raymond and Beverly Sackler Prize in the Physical Sciences in 2013, the Elias J. Corey Award in 2014, and the MacArthur Fellowship in 2016.

J. Silvio Gutkind, PhD

X

J. Silvio Gutkind

J. Silvio Gutkind is a Distinguished Professor in the Department of Pharmacology, School of Medicine, and Associate Director for Basic Science at the Moores Cancer Center, University of California San Diego (UCSD). His research team is exploiting the emerging information on dysregulated signaling circuitries and individual genomic and molecular alterations to develop new precision therapies to prevent and treat cancer, and to identify novel multimodal strategies to enhance the response to cancer immunotherapies. Dr. Gutkind received his PhD in pharmacy and biochemistry from the University of Buenos Aires, Argentina, and after his post-doctoral training at the NIMH and NCI, he joined the NIDCR, NIH. He served as the Chief of the Oral and Pharyngeal Cancer Branch, NIDCR, NIH, since 1998 until his recruitment to UCSD in 2015. He is a scientific advisor of Onceutics, Domain Therapeutics, and Vividion Therapeutics. His honors include the NIH Merit Award, the Elliot Osserman Award from the Israel Cancer Research Foundation, the Pharmaceutical Research and Manufacturers of America (PhRMA) Research & Hope Award, the Distinguished Scientist Award from the International Association of Dental Research (IADR), and the election as the Chair, Division of Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics (ASPET). Dr. Gutkind was recently elected as a Member of the National Academy of Medicine.

Scott A. Biller, PhD

Former CSO at Agios
X

Scott Biller retired as CSO of Agios Pharmaceuticals in 2019. He is currently a senior advisor at Agios and also serves as a strategic advisor to biotech and biopharma. As CSO, Dr. Biller led the efforts to discover two approved medicines, TIBSOVO® and IDHIFA®, for acute myeloid leukemia harboring IDH1 and IDH2 mutations, respectively, and two investigational medicines that are currently in pivotal trials: mitapivat (for pyruvate kinase deficiency) and vorasidenib (for IDH-mutated low grade glioma). Prior to Agios, Dr. Biller held various R&D leadership roles at Novartis and BMS. At BMS, his research focused in the metabolic diseases area, where teams under his leadership discovered multiple investigational medicines and three marketed drugs: the DPP4 inhibitor ONGLYZA® for Type 2 diabetes, the SGLT2 inhibitor FARXIGA® for Type 2 diabetes and the MTP inhibitor JUXTAPID® for familial hypercholesterolemia. Dr. Biller earned a B.S. in chemistry at MIT, a Ph.D. in organic chemistry at Caltech and an NIH Postdoctoral Fellowship at Columbia University.

Bruce D. Roth, PhD

Principal, Roth Pharma Consulting, LLC
X

As a scientific advisor to Vividion, Bruce brings over 35 years of pharma and biopharmaceutical experience. Bruce served as Vice President of Chemistry at the Pfizer Global Research and Development, Ann Arbor Laboratories from 2000-2007. In 2007, Bruce joined Genentech Small Molecule Discovery where he led the Discovery Chemistry Department for seven years before being appointed Senior Vice President, Small Molecule Drug Discovery and co-leader of Research for Genentech Research and Early Development (gRED), the position from which he retired Dec. 31, 2017. After retiring from Genentech, Bruce has stayed active in the biopharmaceutical industry as a consultant, founding his own consulting agency in 2018. He is a member of the Research and Development Advisory Board for ERASCA, Inc., the Scientific Advisory Board for Bolt Biotherapeutics and recently became a senior advisor for Frazier Healthcare Partners. Bruce is best known as the inventor of Lipitor®, for which he has received numerous awards, including the 2003 American Chemical Society Award for Creative Invention, the 2015 National Academy of Sciences Award for Chemistry in Service of Society and the 2013 Perkin Medal, the highest award given to industrial chemists in the United States. Bruce has also been named one of the American Chemical Society Heroes in Chemistry and has been inducted into the Hall of Fame of the American Chemical Society Medicinal Chemistry Division. Bruce received his Ph.D. in organic chemistry from Iowa State University and his B.S. in chemistry from St. Joseph’s College in Philadelphia, PA. He was also a post-doctoral fellow at the University of Rochester and served for over 10 years as an adjunct associate professor in the Department of Medicinal Chemistry in the School of Pharmacy at the University of Michigan.

Christopher T. Walsh, PhD

Hamilton Kuhn Professore of Biological Chemistry at Harvard Medical School
X

Christopher Walsh is a consulting professor to the Stanford University department of chemistry and a senior advisor to the Stanford ChEM-H institute. He is also an advisor to the Chan Zuckerberg BioHub initiative at UCSF and Stanford. He was the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School from 1987-2013. He has had extensive academic leadership experience, including Chairmanship of the MIT Chemistry Dept (1982-1987) and of the HMS Biological Chemistry & Molecular Pharmacology Dept (1987-1995) as well as serving as President and CEO of the Dana Farber Cancer Institute (1992-1995). He is a member of the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and a recipient of the Welch Prize in Chemistry, The Franklin Institute Medal in Chemistry, and the Robert Koch Gold Medal in Infectious Diseases. Additionally, he is on the board of directors of the The Scripps Research Institute.

Don Payan, MD

CEO, Astura Therapuetics
X

Don Payan, MD, was the founder and CSO of the biotechnology companies Khepri and Rigel. He was part of the founding team at Sana Biotechnology, where he is a member of their Board of Directors.
Don has organized and led multidiscipline, targeted drug discovery and development teams in the areas of immunology, oncology and muscle wasting diseases. His teams at Rigel have discovered and developed the first FDA-approved oral SYK inhibitor for an autoimmune disease, as well as an additional 12 IND candidates.
Don began his career as a faculty member in the Department of Medicine at the University of California, San Francisco and the Howard Hughes Medical Institute. He is an author of over 200 published articles and chapters, and holds more than 70 issued patents. He is a member of the American Society of Clinical Investigation.

Jeff Hatfield

Chief Executive Officer
X

Jeff joined Vividion as Chief Executive Officer in November 2020, bringing more than 35 years of successful industry leadership, having held multiple senior executive, CEO and board director roles during his career at both Fortune 500 pharmaceutical and emerging biotechnology companies. Among Mr. Hatfield’s many career leadership roles, he previously served as the CEO of Vitae Pharmaceuticals, Inc., a pioneer in computational structure-based drug discovery, where he led the company from start-up to clinical-stage advancement of multiple first-in-class programs, and ultimately to its $640 million acquisition by Allergan Plc. Earlier, he served as a senior executive at Bristol-Myers Squibb (BMS), where he held roles including senior vice president, Immunology and Virology Divisions; president, BMS-Canada; and head of U.S. market access. Mr. Hatfield currently serves as chairman of the board of miRagen Therapeutics, Inc. and as a board member at aTyr Pharma. He also serves as a Key Advisory Board member for the Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship, and is a faculty member at Purdue University, where he teaches entrepreneurship to doctoral students. Mr. Hatfield holds an MBA from The Wharton School, University of Pennsylvania, and a B.S. from the Purdue University College of Pharmacy.

Patty Allen

Chief Financial Officer
X

Patty Allen serves as Chief Financial Officer of Vividion, Inc. She is a business, finance and operations leader with more than 25 years of experience leading and advising financial and investor relations functions at private and public companies. Patty currently serves on multiple boards of directors for both private and public biotechnology companies. Earlier, she served in financial related roles of increasing responsibility across the biotechnology industry, including at Alnylam, Alkermes and Zafgen. Across those positions, she played an influential role in raising more than $1 billion in both private and public offerings. Patty began her career as an auditor at Deloitte & Touche, LLP. Patty graduated summa cum laude from Bryant College with a B.S. in business administration.

Bob Abraham

Chief Scientific Officer
X

Robert (Bob) Abraham is the Chief Scientific Officer at Vividion Therapeutics. From 2015-2019, Bob was the Senior Vice President and Group Head of the Oncology R&D (ORD) Group in Pfizer Worldwide Research, Development, and Medical (WRDM). Before joining Pfizer, Bob served as Vice President of Oncology Research at Wyeth Discovery Research from 2005-2009. Prior to joining Wyeth, Bob was a Professor at the Sanford-Burnham-Prebys Medical Discovery Institute (SBPMDI) in La Jolla, CA. He was the founding Director of the Signal Transduction Research Program and served as the Director of the SBPMDI Cancer Research Center, successfully guiding the center to a renewal of its designation as one of nine National Cancer Institute-sponsored basic science centers in the United States. Bob retains an appointment as an Adjunct Professor at the SBPMDI, together with an Adjunct Professor Appointment in Pharmacology at the University of California-San Diego. From 1998-2001, Bob was a Professor in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center and was the first recipient of the Glaxo-Wellcome Chair of Molecular Cancer Biology at Duke. He also served as Associate Director of Translational Research in the Duke Comprehensive Cancer Center. Before his arrival at Duke University, Bob was at the Mayo Clinic in Rochester, MN, where he rose through the ranks from postdoctoral fellow to Professor in both the Department of Immunology and the Department of Pharmacology. From 1997-1998, he also served as Director of Basic Sciences in the Mayo Comprehensive Cancer Center. Bob received his B.S. in Biology from Bucknell University, Lewisburg, PA in 1974 and subsequently completed his Ph.D. studies in Pharmacology at the University of Pittsburgh, Pittsburgh, PA.

Larry Burgess

Head of Chemistry
X

Larry joined Vividion in September 2018 as Head of Chemistry, bringing extensive scientific leadership and drug development experience to the company. Larry previously served as Vice President of Medicinal Chemistry for Array BioPharma, where he helped to advance many discovery programs that resulted in Investigational New Drug (IND) applications. The majority of those drugs are currently being tested in patients or are approved.
Prior to joining Array BioPharma, Larry was at Amgen and Pfizer. He received a B.S. in chemistry from the Georgia Institute of Technology, a Ph.D. from the University of Texas and completed his postdoctoral research at Colorado State University.

Todd Kinsella

Head of Biology
X

Todd Kinsella joined Vividion in 2017 as Vice President of Translational and Development Sciences. Todd supports all stages of Vividion’s therapeutic pipeline from target identification, validation, drug discovery and the translational biology interface connecting pre-clinical programs and development.

Prior to joining Vividion, Todd served as Vice President of Research at Rigel Pharmaceuticals with over 18 years of experience in small molecule and antibody-based drug discovery. He was instrumental in establishing Rigel’s original flagship technology for discovering novel drugable targets. He has founded and served as head of numerous departments within Rigel, and led key drug discovery programs within target discovery-immunology, virology, muscle, metabolism, vascular biology and immuno-oncology.

Todd received his BS in Molecular and Cellular Biology from the University of Arizona and PhD in Molecular Pharmacology from Stanford University. He is an author of 15 published articles and an inventor on 26 issued patents.

Jean Bemis

Head of Alliance Management
X

Jean Bemis is Head of Alliance Management at Vividion and has more than 25 years of experience in drug development, from early discovery through IND acceptance and clinical study initiation. Jean was previously involved in new company formation at Gene Sciences, Inc., Rodin Therapeutics and Warp Drive Bio, leading program management and drug development. Prior to that, Jean was an early employee of Catabasis Pharmaceuticals, leading the chemistry group from preclinical discovery to CMC campaigns to support clinical studies. In addition to biotherapeutic start-ups, Jean’s experience also
includes driving programs forward at Amgen, GSK and Wyeth.

Matt Patricelli

Head of Early Discovery
X

Matt Patricelli joined Vividion in 2016 as a founding scientific member of the company’s management team.  In his current role, Matt supports all early drug discovery efforts including target selection and validation, as well as the continued development and execution of Vividion’s chemical proteomics platform.

Prior to joining Vividion, Matt served as the Senior Director of Biology at Wellspring Biosciences where he led several drug discovery programs including the KRAS-G12C covalent inhibitor discovery project.  From 2000-2012 Matt led the chemical proteomics platform activities at ActivX Biosciences. He was the first Scientist to join ActivX and played a key role in the development of ActivX’s platform technologies, including establishing the KiNativ platform which continues to operate as a successful commercial screening service.

Matt obtained his BSc in Biochemistry from McGill University, and PhD from The Scripps Research Institute as the first graduate student of Vividion founder Dr. Benjamin Cravatt.  He is an author or co-author of more than 30 scientific publications, and 3 issued patents.

Dean Stamos

Head of Chemistry Innovation
X

Dr. Dean Stamos joined Vividion Therapeutics in 2017 as Vice President of Chemistry. In his current role, Dean oversees the strategic growth and implementation of Vividion’s cutting edge chemical proteomics platform to support all aspects of the drug discovery process. Central towards this goal is the full utilization of modern synthetic methodologies coupled with chemical biology insights to deliver high-quality small molecule therapeutics.

Dean joined Vividion with 20 years of leadership experience at Vertex Pharmaceuticals working in multiple therapeutic areas including infectious disease, oncology, inflammation, pain, and neurodegeneration delivering multiple pre-clinical and clinical stage assets. In addition, Dean lead various functions integral to drug discovery including hit to lead, analytical, scale up, and library synthesis as well as the creation of an integrated chemical biology group. As a passionate supporter of exploring novelty and change at the interfaces of chemistry, biology, and leadership, Dean initiated and chaired several internal and external collaborations in the areas of ligand-receptor kinetics, C-H activation, natural products research, and change management.

Dean received his BS in Chemistry from Indiana University, and a PhD in Organic Chemistry from Harvard University. He is an author of 26 published articles and an inventor on 21 patents.

Brian Koh

Head of Translational Sciences and Clinical Development
X

Head of Translational Sciences and Clinical Development
Brian joined the Vividion team in 2021 as Head of Translational Sciences and Clinical Development. He previously served in positions of increasing responsibility at both Gilead Sciences and Kite Pharma leading programs and studies in early through late stages of clinical development of targeted, immuno-oncological, and cellular therapies in both solid and hematological malignancies.

Brian received an A.B. in biological anthropology from Harvard College and an M.D. as well as an M.S. and M.Phil. from Yale University, the latter for graduate work in chemical biology. At Mayo Clinic-Rochester, he completed a postdoctoral fellowship in clinical pharmacology as well as postgraduate medical education in internal medicine, hematology, and medical oncology under the auspices of the Clinician Investigator Training Program/ABIM Research Pathway while holding a triple academic appointment as an instructor in the departments of medicine, oncology, and pharmacology.

Lisa Percival

Head of Regulatory
X

Lisa is a regulatory and clinical research professional who brings more than 25 years of experience to Vividion. She joins the company from Atlas Venture, where she has served as an entrepreneur in residence, regulatory strategy and as senior vice president, regulatory affairs for an Atlas stealth company. Prior to joining Atlas, Ms. Percival was vice president of regulatory affairs at Zafgen, Inc., where she was responsible for the development and execution of the global regulatory strategy for products to treat metabolic diseases and partnered with the executive team on business strategy. Before Zafgen, she worked for Bristol-Myers Squibb in clinical development and global regulatory strategy and policy, where she led the global pediatric center of excellence in support of all therapeutic areas and led global regulatory teams in virology, immunoscience and fibrosis to successful completion of clinical trials and IND, NDA, MAA and other global submissions and approvals. Ms. Percival holds an M.S. in physiology from the University of Connecticut and a B.S. in biology from Trinity College.

Xiaohu Deng

Head of Technical Operations
X

Xiaohu brings more than 20 years of experience in the biotechnology industry with a focus on drug product development and technical operations. Dr. Deng joins Vividion from Viracta Therapeutics, Inc. where he served as senior vice president, product development, leading the CMC function and IP strategy. Prior to that, he was a senior director, head of CMC at Kura Oncology, Inc. and Wellspring Biosciences, Inc., overseeing the CMC efforts on process R&D, manufacturing, compliance, regulatory and clinical supply for multiple programs through various phases of development. Earlier in his career, Dr. Deng held roles of increasing responsibility associated with chemistry R&D, CRO management and project management of discovery and preclinical development at Janssen Pharmaceutical Companies of Johnson & Johnson. Dr. Deng holds a Ph.D. in organic chemistry from Emory University, and an M.S. in physical chemistry and a B.S. in chemistry from Fudan University in Shanghai. Dr. Deng has more than 40 journal publications, a book chapter and holds 16 published patents.

Jeff Hatfield

Chief Executive Officer
X

Jeff joined Vividion as Chief Executive Officer in November 2020, bringing more than 35 years of successful industry leadership, having held multiple senior executive, CEO and board director roles during his career at both Fortune 500 pharmaceutical and emerging biotechnology companies. Among Mr. Hatfield’s many career leadership roles, he previously served as the CEO of Vitae Pharmaceuticals, Inc., a pioneer in computational structure-based drug discovery, where he led the company from start-up to clinical-stage advancement of multiple first-in-class programs, and ultimately to its $640 million acquisition by Allergan Plc. Earlier, he served as a senior executive at Bristol-Myers Squibb (BMS), where he held roles including senior vice president, Immunology and Virology Divisions; president, BMS-Canada; and head of U.S. market access. Mr. Hatfield currently serves as chairman of the board of miRagen Therapeutics, Inc. and as a board member at aTyr Pharma. He also serves as a Key Advisory Board member for the Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship, and is a faculty member at Purdue University, where he teaches entrepreneurship to doctoral students. Mr. Hatfield holds an MBA from The Wharton School, University of Pennsylvania, and a B.S. from the Purdue University College of Pharmacy.

Christine Siu

Christine Siu
X

Ms. Siu brings a strong track record of creating value and integrating financing strategy with corporate development to the Vividion board of directors. Ms. Siu is the chief operating officer in-residence at BridgeBio Pharma, Inc, and former chief financial officer at Eidos Therapeutics, Inc., a BridgeBio subsidiary, where she transformed Eidos from a preclinical biotech start-up company to a late-stage clinical public company. Prior to that, she was the chief business officer at The Bluefield Project to Cure Frontotemporal Dementia, where she built a therapeutic pipeline and executed seven collaborations with the pharmaceutical industry. Earlier, she was senior director, corporate development at Global Blood Therapeutics, Inc. (GBT), and before that, a venture principal at Third Rock Ventures, where she was part of the GBT launch team and first employee at GBT. Previously, Ms. Siu invested in life science companies in venture capital and private equity and held roles of increasing responsibility at Warburg Pincus LLC and Thomas, McNerney & Partners, LLC and began her career in healthcare banking at Bear, Stearns & Co. Inc. Ms. Siu holds an MBA from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan.

Kristina Burow

X

Kristina Burow is a Managing Director with ARCH Venture Partners. Ms. Burow is a director of Vividion, Lycera, BlackThorn Therapeutics, Sienna Biopharmaceuticals, Metacrine, Scholar Rock, Unity Biotechnology, AgBiome and Vir Biotechnology, and was a co-founder and director of Receptos (RCPT – acquired by Celgene). She participated in other ARCH portfolio companies including Siluria Technologies, Kythera (KYTH – acquired by Allergan), Ikaria (acquired by Madison Dearborn) and Sapphire Energy (co-founder). Prior to joining ARCH in 2002, Ms. Burow was an Associate with the Novartis BioVenture Fund and was active in Chemistry Operations and Business Development at the Genomics Institute of the Novartis Research Foundation. Ms. Burow holds a M.B.A. from the University of Chicago, a M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.

John K. Clarke

X

John K. Clarke has a 30 year record of early-stage venture capital investment success. John co-founded Cardinal Partners in 1997 and currently serves as a Managing Partner of the firm. John leads Cardinal’s life sciences investment efforts and has had an extraordinary record of success.

Mr. Clarke led the firm’s investment in Cubist Pharmaceuticals, Momenta Pharmaceuticals, Alnylam Pharmaceuticals, and Sirtris Pharmaceuticals. He also spearheaded Cardinal’s investment in and served as a director for: TechRx Corporation and Visicu. Mr. Clarke currently serves on the Board of Directors for Cardinal portfolio companies Abide Therapeutics, aTyr Pharma, Rib-X Pharmaceuticals (observer) and Verastem, as well as Alnylam Pharmaceuticals and Momenta Pharmaceuticals.John entered the venture industry in 1982 with DSV Partners, a pioneer venture capital fund formed in 1968. Additionally, he led DSV’s health care and life sciences efforts, and was a co-founder and served as interim CEO of numerous successful companies including Alkermes, Arris Pharmaceuticals, DNX and Cubist Pharmaceuticals. As managing partner at DSV in that firm’s latter years, Mr. Clarke led the firm’s evolution into Cardinal Partners.

Mr. Clarke received his B.A. in Economics and Biology from Harvard University and his M.B.A. from the Wharton School at the University of Pennsylvania.

Jakob Loven

X

Jakob Loven, Ph.D., joined Nextech Invest as Partner in 2017, bringing the passion of a serial entrepreneur. Jakob joined Nextech from Third Rock, where he focused on new company formation in the areas of oncology and emerging technologies. He also served on the firm’s scientific ideation team, overseeing several early-stage projects and leading efforts to transform emerging areas of science into innovative drug discovery companies with unique scientific platforms. While at Third Rock, Jakob launched Relay Therapeutics in Cambridge Massachusetts, which was selected as one of Fiercebiotech’s Fierce 15 in 2017. Prior to Relay, Jakob was a Founding Scientist of Syros Pharmaceuticals (NASDAQ: SYRS), which was founded on his co-discoveries in gene regulation sciences and technologies. Jakob holds a BA in Biomedical Sciences from the Anglia Ruskin University of Cambridge, earned his Ph.D. in Medical Sciences from Karolinska Institutet, and conducted his postdoctoral fellowship at the Whitehead Institute for Biomedical Research. During his appointment at the Whitehead Institute, Jakob pioneered the field of gene regulation research through numerous scientific findings, authoring several high-impact journal articles.

Jakob manages Nextech’s investments in Autolus, A2 Biotherapeutics, Arvinas and Turning Point Therapeutics.

Benjamin F. Cravatt

X

Benjamin F. Cravatt is a Professor and Co-Chair of the Department of Molecular Medicine at The Scripps Research Institute. His research group is interested in understanding the roles that enzymes play in physiological and pathological processes, especially as pertains to the nervous system and cancer.  Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History.  He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996. Professor Cravatt joined the faculty at TSRI in 1997. Dr. Cravatt is a co-founder and scientific advisor of Activx Biosciences, Abide Therapeutics, and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the Protein Society Irving Sigal Young Investigator Award, the Tetrahedron Young Investigator Award in Bioorganic and Medicinal Chemistry, the ASBMB Merck Award, and memberships in the National Academy of Sciences and American Academy of Arts and Sciences.

Thomas O. Daniel

X

Tom has contributed to innovative healthcare solutions as a practicing physician, scientist, educator, research executive and entrepreneur. Currently Venture Partner at ARCH Venture Partners, he previously led Research & Early Development at Celgene Corporation, where he and colleagues established new corporate collaboration approaches and advanced to approval multiple impactful medicines in oncology and inflammatory diseases. Formerly in senior R&D leadership positions at Immunex, Amgen, and Ambrx, he currently Chairs Locana Bio, and serves as Director at Magenta Therapeutics, Zafgen, VIR Bio, Sana Therapeutics, and Gossamer Bio. He chairs the Board of Overseers of The Scripps Research Institute, advises Vanderbilt University Medical Center, the Parker Institute for Cancer Immunotherapy, is a Trustee of Reed College, and serves as Director for the Lupus Research Alliance. He obtained his undergraduate degree at Southern Methodist University, his medical degree at UT-Southwestern Medical School, trained in Internal Medicine at Massachusetts General Hospital, and was formerly Hakim Professor of Medicine at Vanderbilt.

Catherine Friedman

X

Catherine Friedman is a financial industry expert with nearly 40 years of financial industry experience. Since 2006, she has been an independent financial consultant serving public and private companies in the life sciences industry. Previously, Ms. Friedman held numerous executive positions during a 23-year investment banking career with Morgan Stanley, including managing director, and head of West Coast Healthcare, and co-head of the Biotechnology Practice. Ms. Friedman is the chair of the board of directors for GRAIL, Inc. and also serves as a member of the boards of Altaba Inc. (formerly Yahoo! Inc.), Radius Health and Lyell Immunopharma, Inc. She is a trustee of The Darden School Foundation at the University of Virginia. Ms. Friedman holds a B.A. in economics from Harvard University and an MBA from The University of Virginia’s Darden School of Business.

Richard Heyman

Chairman
X

Richard Heyman currently serves as Chairman of the Board and Co-founder of Metacrine Inc., a biotech company developing innovative drugs for patients with metabolic disease.  Previously, he was the co-founder and CEO of Aragon and Seragon Pharmaceuticals; two San Diego biotech companies focused on discovering and developing next generation therapeutics for hormone dependent cancers.  Johnson & Johnson purchased Aragon in 2013 and Genentech/Roche purchased Seragon in 2014.  Following his post-doctoral training at the Salk Institute, Dr. Heyman joined and held various roles at Ligand Pharmaceuticals, including Vice President of Research

Dr. Heyman is also actively involved in ORIC Pharmaceuticals, an oncology based biotech company where he serves as a board member and served as interim CEO from in 2015/2016.  He also serves on the boards of Gritstone Oncology and Yumanity Therapeutics and was a Board member of Receptos Inc. (recently sold to Celgene).  Dr. Heyman serves as Vice Chair on the Board of Trustees of the Salk Institute for Biological Studies, Board Foundation for the AACR and both the Executive Committee and Board of Visitors at the UCSD Moores Cancer Center. Dr. Heyman received a PhD in pharmacology and a BS in chemistry.   He is the author or inventor on more than 120 publications and patents.

Thomas Woiwode

X

Thomas Woiwode has been with Versant Ventures since 2002, serving as a Venture Partner since 2011 and a Managing Director since 2014.  Mr. Woiwode has served in a number of operating roles over this time, most recently as the Chief Operating Officer of Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases. He led the process that culminated in the sale of Okairos to GlaxoSmithKline for $325M. Prior to his role with Okairos, Mr. Woiwode co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding Chief Business Officer for three biotech companies created within Versant: Flexion (public), Synosia (public, merged with BioTie), and Amira (acquired by Bristol-Myers Squibb for up to $475M). Prior to his role as a Venture Partner, he was an Associate at Versant Ventures and served on the boards of Antipodean, Metabolex and Saegis. Mr Woiwode was a research scientist at XenoPort before joining Versant. He earned his PhD in Organic Chemistry as an NSF Fellow at Stanford University and graduated summa cum laude with a BA in English and received the Departmental Citation for his B.S. in Chemistry from UC Berkeley.

Mr. Woiwode currently serves on the boards of Annapurna, Anokion, Audentes, CRISPR, Gritstone, Kanyos Bio, and Therachon.

Latest News

May 4, 2021

Vividion Therapeutics Appoints Christine Siu to Board of Directors
Read Press Release

April 21, 2021

Vividion Expands Leadership Team with Key Regulatory and CMC Appointments
Read Press Release

March 30, 2021

Vividion Names Patty Allen as Full-Time Chief Financial Officer and Welcomes Brian Koh, M.D., as Head of Translational Sciences and Clinical Development
Read Press Release

Careers

Our mission is to leverage our unique insights into finding and binding cryptic functional pockets on currently intractable human biology-validated protein targets to discover, develop and commercialize small molecule therapies that can transform the lives of patients suffering from devastating cancers and immune disorders. Join us in our mission.

+Job Openings
+Recruiting Privacy Notice

Investors